Sanofi (NYSE:SNY) filed a patent infringement suit against Mylan (NSDQ:MYL) yesterday in the U.S. District Court of New Jersey, alleging that the EpiPen-maker infringed upon 18 patents covering Sanofi’s Lantus insulin glargine injection and SoloStar pen.
The suit was triggered by a notice from Mylan in mid-September, Sanofi said. Mylan told the insulin-maker that it had filed an NDA for an insulin glargine pre-filled pen, which challenged all of the patents listed for Sanofi’s Lantus products.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi files patent infringement suit against Mylan over insulin pen appeared first on MassDevice.
from MassDevice http://ift.tt/2h834tt
Cap comentari:
Publica un comentari a l'entrada